Dashboard
Manage Tickers

BCABBioAtla, Inc.

Nasdaq bioatla.com


$ 1.68 $ 0.00 (0 %)    

Tuesday, 17-Sep-2024 09:44:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 475.68 $ -0.29 (-0.06 %)
DIA $ 417.70 $ -0.29 (-0.07 %)
SPY $ 564.74 $ -0.39 (-0.07 %)
TLT $ 101.11 $ -0.28 (-0.28 %)
GLD $ 237.99 $ 0.01 (0 %)
$ 1.68
$ 1.67
$ 1.66 x 300
$ 1.67 x 605
$ 1.66 - $ 1.68
$ 1.14 - $ 4.02
759,324
na
81.2M
$ 2.58
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-26-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-01-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-23-2023 12-31-2022 10-K
8 11-04-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-12-2021 03-31-2021 10-Q
15 03-24-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jmp-securities-reiterates-market-outperform-on-bioatla-maintains-5-price-target
JMP Securities Reiterates Market Outperfor...
09/16/2024 13:54:52

JMP Securities analyst Reni Benjamin reiterates BioAtla (NASDAQ:BCAB) with a Market Outperform and maintains $5 price target.

bioatla-presented-phase-2-ozuriftamab-vedotin-clinical-trial-data-demonstrating-meaningful-antitumor-activity-with-manageable-tolerability-among-heavily-pretreated-patients-with-squamous-cell-carcinoma-of-the-head-and-neck-at-the-2024-esmo-annual-meeting
BioAtla Presented Phase 2 Ozuriftamab Vedo...
09/16/2024 12:22:13

An ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens Underscores oz...

big-short-fame-michael-burry-bets-big-on-china-reveals-alibaba-as-top-holding--jdcom-and-baidu-also-feature-on-scions-portfolio
'Big Short' Fame Michael Burry Bets Big On...
08/15/2024 05:19:34

Famed investor Michael Burry, known for his prescient bet against the housing market before the 2008 financial crisis, has made...

Core News & Articles
Watching Shares Of BioAtla, Olaplex Holdin...
08/14/2024 18:38:24

bioatla-q2-2024-gaap-eps-044-inline
BioAtla Q2 2024 GAAP EPS $(0.44), Inline
08/08/2024 20:27:38

BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.44) per share which met the analyst consensus estimate.

bioatla-provides-clinical-program-and-pipeline-updates-at-rd-day
BioAtla Provides Clinical Program And Pipe...
07/25/2024 21:42:20

bioatla-granted-fda-fast-track-designation-for-ozuriftamab-vedotin-for-treatment-of-patients-with-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck
BioAtla Granted FDA Fast Track Designation...
07/23/2024 12:16:04

Ozuriftamab vedotin, the Company's conditionally and reversibly active antibody drug conjugate directed against ROR2, has s...

jmp-securities-maintains-market-outperform-on-bioatla-lowers-price-target-to-5
JMP Securities Maintains Market Outperform...
05/23/2024 16:09:25

JMP Securities analyst Reni Benjamin maintains BioAtla (NASDAQ:BCAB) with a Market Outperform and lowers the price target fr...

hc-wainwright--co-reiterates-buy-on-bioatla-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on BioA...
05/15/2024 15:19:29

HC Wainwright & Co. analyst Arthur He reiterates BioAtla (NASDAQ:BCAB) with a Buy and maintains $7 price target.

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
05/14/2024 20:31:13

bioatla-q1-2024-gaap-eps-048-beats-054-estimate
BioAtla Q1 2024 GAAP EPS $(0.48) Beats $(0...
05/14/2024 20:23:31

BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.54) by 11...

bioatla-announces-fda-clearance-of-investigational-new-drug-application-for-ba3361
BioAtla Announces FDA Clearance Of Investi...
05/06/2024 12:07:44

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
05/02/2024 16:31:17

jmp-securities-reiterates-market-outperform-on-bioatla-maintains-12-price-target
JMP Securities Reiterates Market Outperfor...
03/28/2024 14:34:55

JMP Securities analyst Reni Benjamin reiterates BioAtla (NASDAQ:BCAB) with a Market Outperform and maintains $12 price target.

hc-wainwright--co-maintains-buy-on-bioatla-lowers-price-target-to-7
HC Wainwright & Co. Maintains Buy on BioAt...
03/27/2024 10:26:29

HC Wainwright & Co. analyst Arthur He maintains BioAtla (NASDAQ:BCAB) with a Buy and lowers the price target from $10 to...

bioatla-q4-eps-056-beats-079-estimate
BioAtla Q4 EPS $(0.56) Beats $(0.79) Estimate
03/26/2024 21:35:40

BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.79) by 29...

bioatla-q4-earnings-insights
BioAtla: Q4 Earnings Insights
03/26/2024 21:35:13

earnings-scheduled-for-march-26-2024
Earnings Scheduled For March 26, 2024
03/26/2024 08:47:27

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

preview-bioatlas-earnings
Preview: BioAtla's Earnings
03/25/2024 16:00:39

around-2m-bet-on-this-healthcare-stock-check-out-these-4-penny-stocks-insiders-are-aggressively-buying
Around $2M Bet On This Healthcare Stock? C...
12/20/2023 13:31:54

The Dow Jones index closed higher by around 250 points on Tuesday. When insiders purchase or sell shares, it indicates their co...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION